Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13536909 | 0.93 | PKM (0.70) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL1932281 | 0.89 | PKM (0.65) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL8193968 | 0.86 | PKM (0.96) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL10409988 | 0.86 | PKM (0.96) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL4102676 | 0.86 | PKM (0.96) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL436674 | 0.86 | PKM (0.89) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL1930631 | 0.85 | PKM (0.61) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL8502340 | 0.84 | PKM (1.00) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL7953663 | 0.84 | PKM (1.00) | PKMALDH1A1HTTPOLBKMT2A | |
| SCHEMBL5564371 | 0.84 | KMT2A (0.86) | PKMALDH1A1HTTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322079-A1 | LOW CATALYST LOADING IN METATHESIS REACTIONS | EVONIK INDUSTRIES AG (DE) | 2015-11-12 | — | — | US | disclosed |
| US-20150322079-A1 | LOW CATALYST LOADING IN METATHESIS REACTIONS | EVONIK INDUSTRIES AG (DE) | 2015-11-12 | — | — | US | disclosed |
| EP-2711351-A1 | Low catalyst loading in metathesis reactions | Evonik Industries AG (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-7612008-B2 | Metathesis catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322079-A1 | LOW CATALYST LOADING IN METATHESIS REACTIONS | APEX1, PMS2, MAX | PKM 1682/4885ALDH1A1 2091/4885HTT 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.